Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids

Drug Metabolism Reviews

Volumn 46, Issue 1, 2014, Pages 33-56

  Shahabi, Payman ^a   Siest, Gérard ^a   Visvikis Siest, Sophie ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Cytochrome P450; Epoxyeicosatrienoic acids; Epoxygenase; Inflammation; Nuclear transcription factor kappa B; Soluble epoxy hydrolase

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYTOCHROME P450; CYTOCHROME P450 EPOXYGENASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOXYICOSATRIENOIC ACID; HEME OXYGENASE 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARACHIDONIC ACID METABOLISM; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME STRUCTURE; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; FIBRINOLYSIS; HEART FUNCTION; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYDRATION; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASODILATATION;

ANIMALS; ARACHIDONIC ACID; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INFLAMMATION;

EID: 84893222952     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.837916     Document Type: Review

References (280)

1. Abraham NG, Jiang S, Yang L, et al. (2000). Adenoviral vector-mediated transfer of human heme oxygenase in rats decreases renal hemedependent arachidonic acid epoxygenase activity. J Pharmacol Exp Ther 293:494-500.
2. Abraham NG, Kappas A. (2008). Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60:79-127.
3. Aggarwal BB. (2004). Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203-208.
4. Aitken AE, Lee CM, Morgan ET. (2008). Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med 44:1161-1168.
5. Aitken AE, Morgan ET. (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35:1687-1693.
6. Aitken AE, Richardson TA, Morgan ET. (2006). Regulation of drugmetabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149.
7. Amit Y, Boneh A. (1993). Bilirubin inhibits protein kinase C activity and protein kinase C-mediated phosphorylation of endogenous substrates in human skin fibroblasts. Clin Chim Acta 223:103-111.
8. Anwar-mohamed A, Zordoky BN, Aboutabl ME, El-Kadi AO. (2010). Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 61:410-418.
9. Archer SL, Gragasin FS, Wu X, et al. (2003). Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12- epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation 107:769-776.
10. Back M. (2009). Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 15:3116-3132.
11. Batchu SN, Law E, Brocks DR, et al. (2009). Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 46:67-74.
12. Beigneux AP, Moser AH, Shigenaga JK, et al. (2002). Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem Biophys Res Commun 293:145-149.
13. Belcher JD, Mahaseth H, Welch TE, et al. (2006). Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 116:808-816.
14. Beltran B, Mathur A, Duchen MR, et al. (2000). The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death. Proc Natl Acad Sci USA 97:14602-14607.
15. Berg AH, Scherer PE. (2005). Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939-949.
16. Bernstrom K, Kayganich K, Murphy RC, Fitzpatrick FA. (1992). Incorporation and distribution of epoxyeicosatrienoic acids into cellular phospholipids. J Biol Chem 267:3686-3690.
17. Bieche I, Narjoz C, Asselah T, et al. (2007). Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742.
18. Bishop-Bailey D. (2000). Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 129:823-834.
19. Bocher V, Chinetti G, Fruchart JC, Staels B. (2002). Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. J Soc Biol 196:47-52.
20. Bottex-Gauthier C, Pollet S, Favier A, Vidal DR. (2002). The Rel/NFkappa- B transcription factors: Complex role in cell regulation. Pathol Biol (Paris) 50:204-211.
21. Brash AR. (1999). Lipoxygenases: Occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274:23679-23682.
22. Burgess A, Vanella L, Bellner L, et al. (2012a). Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. Prostaglandins Other Lipid Mediat 97:1-16.
23. Burgess AP, Vanella L, Bellner L, et al. (2012b). Heme oxygenase (HO-1) rescue of adipocyte dysfunction in HO-2 deficient mice via recruitment of epoxyeicosatrienoic acids (EETs) and adiponectin. Cell Physiol Biochem 29:99-110.
24. Bystrom J, Wray JA, Sugden MC, et al. (2011). Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 6:e26591.
25. Cai Z, Zhao G, Yan J, et al. (2013). CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aorticaneurysm in mice. J Lipid Res 54:1448-1456.
26. Campbell WB. (2000). New role for epoxyeicosatrienoic acids as antiinflammatory mediators. Trends Pharmacol Sci 21:125-127.
27. Campbell WB, Falck Jr. (2007). Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49: 590-596.
28. Campbell WB, Fleming I. (2010). Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 459:881-895.
29. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
30. Campbell WB, Holmes BB, Falck JR, et al. (2006). Regulation of potassium channels in coronary smooth muscle by adenoviral expression of cytochrome P-450 epoxygenase. Am J Physiol Heart Circ Physiol 290:H64-H71.
31. Capdevila JH, Falck Jr. (2000). Biochemical and molecular characteristics of the cytochrome P450 arachidonic acid monooxygenase. Prostaglandins Other Lipid Mediat 62:271-292.
32. Capdevila JH, Falck Jr. (2002). Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69:325-344.
33. Capdevila JH, Falck JR, Harris RC. (2000). Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181.
34. Carey MA, Germolec DR, Langenbach R, Zeldin DC. (2003). Cyclooxygenase enzymes in allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 69:157-162.
35. Chataigneau T, Feletou M, Duhault J, Vanhoutte PM. (1998). Epoxyeicosatrienoic acids, potassium channel blockers and endothelium- dependent hyperpolarization in the guinea-pig carotid artery. Br J Pharmacol 123:574-580.
36. Chatterjee TK, Stoll LL, Denning GM, et al. (2009). Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ Res 104:541-549.
37. Chaudhary KR, Batchu SN, Das D, et al. (2009). Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. Cardiovasc Res 83:362-370.
38. Chawengsub Y, Gauthier KM, Campbell WB. (2009). Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 297:H495-H507.
39. Chen JK, Capdevila J, Harris RC. (2001). Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21:6322-6331.
40. Chen JK, Capdevila J, Harris RC. (2002). Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci USA 99:6029-6034.
41. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. (1999). Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55:288-295.
42. Chen JK, Falck JR, Reddy KM, et al. (1998). Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem 273: 29254-29261.
43. Chen R, Jiang J, Xiao X, Wang D. (2005). Effects of epoxyeicosatrienoic acids on levels of eNOS phosphorylation and relevant signaling transduction pathways involved. Sci China C Life Sci 48:495-505.
44. Chen D, Whitcomb R, MacIntyre E, et al. (2012). Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J Clin Pharmacol 52:319-328.
45. Chen X, Sood S, Yang CS, et al. (2006). Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets 6:613-622.
46. Chen Y, Falck JR, Tuniki VR, Campbell WB. (2009). 20-125Iodo-14,15- epoxyeicosa-5(Z)-enoic acid: A high-affinity radioligand used to characterize the epoxyeicosatrienoic acid antagonist binding site. J Pharmacol Exp Ther 331:1137-1145.
47. Cheng LM, Jiang JG, Sun ZY, et al. (2010). The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells. Acta Pharmacol Sin 31:211-218.
48. Chmurzynska A. (2006). The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism. J Appl Genet 47:39-48.
49. Clemetson KJ, Clemetson JM, Proudfoot AE, et al. (2000). Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96:4046-4054.
50. Coats P, Johnston F, MacDonald J, et al. (2001). Endothelium-derived hyperpolarizing factor: Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 103:1702-1708.
51. Cohen RA, Vanhoutte PM. (1995). Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349.
52. Cowart LA, Wei S, Hsu MH, et al. (2002). The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator- activated receptor ligands. J Biol Chem 277: 35105-35112.
53. Daikh BE, Lasker JM, Raucy JL, Koop DR. (1994). Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 271:1427-1433.
54. Dattilo JB, Makhoul RG. (1997). The role of nitric oxide in vascular biology and pathobiology. Ann Vasc Surg 11:307-314.
55. Davis ME, Grumbach IM, Fukai T, et al. (2004). Shear stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor kappaB binding. J Biol Chem 279:163-168.
56. Delerive P, Fruchart JC, Staels B. (2001). Peroxisome proliferatoractivated receptors in inflammation control. J Endocrinol 169: 453-459.
57. Delozier TC, Kissling GE, Coulter SJ, et al. (2007). Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
58. Deng Y, Theken KN, Lee CR. (2010). Cytochrome P450 epoxygenases, soluble epoxide hydrolase and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 48:331-341.
59. Dhanasekaran A, Al-Saghir R, Lopez B, et al. (2006). Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol 291:H517-H531.
60. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, et al. (2008). Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 294:H724-H735.
61. Dimitropoulou C, West L, Field MB, et al. (2007). Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat 83:50-61.
62. Dratewka-Kos E, Tinker DO, Kindl B. (1986). Unsaturated fatty acids inhibit ADP-arachidonate-induced platelet aggregation without affecting thromboxane synthesis. Biochem Cell Biol 64:906-913.
63. Earley S, Heppner TJ, Nelson MT, Brayden JE. (2005). TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res 97:1270-1279.
64. Edin ML, Wang Z, Bradbury JA, et al. (2011). Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J 25:3436-3447.
65. Elbekai RH, El-Kadi AO. (2006). Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Ther 112: 564-587.
66. Enayetallah AE, French RA, Thibodeau MS, Grant DF. (2004). Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52: 447-454.
67. Endemann DH, Schiffrin EL. (2004). Endothelial dysfunction. J Am Soc Nephrol 15:1983-1992.
68. Falck JR, Krishna UM, Reddy YK, et al. (2003a). Comparison of vasodilatory properties of 14,15-EET analogs: Structural requirements for dilation. Am J Physiol Heart Circ Physiol 284:H337-H349.
69. Falck JR, Reddy LM, Reddy YK, et al. (2003b). 11,12-epoxyeicosatrienoic acid (11,12-EET): Structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett 13: 4011-4014.
70. Fang X, Kaduce TL, Weintraub NL, et al. (1996). Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 79:784-793.
71. Fang X, Kaduce TL, Weintraub NL, et al. (2001). Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276:14867-14874.
72. Fang X, Kaduce TL, Weintraub NL, Spector AA. (1997). Cytochrome P450 metabolites of arachidonic acid: Rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 57:367-371.
73. Fang X, Moore SA, Stoll LL, et al. (1998). 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol 275:H2113-H2121.
74. Fang X, Weintraub NL, Oltman CL, et al. (2002). Human coronary endothelial cells convert 14,15-EET to a biologically active chainshortened epoxide. Am J Physiol Heart Circ Physiol 283: H2306-H2314.
75. Fang X, Weintraub NL, Stoll LL, Spector AA. (1999). Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 34:1242-1246.
76. Feletou M, Vanhoutte PM. (2006). Endothelium-derived hyperpolarizing factor: Where are we now? Arterioscler Thromb Vasc Biol 26: 1215-1225.
77. Fisslthaler B, Popp R, Kiss L, et al. (1999). Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401:493-497.
78. Fitzpatrick FA, Ennis MD, Baze ME, et al. (1986). Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261: 15334-15338.
79. Fleming I. (2007b). Discreet regulators of homeostasis: Epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation. Trends Pharmacol Sci 28:448-452.
80. Fleming I. (2007c). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82:60-67.
81. Fleming I. (2011). The cytochrome P450 pathway in angiogenesis and endothelial cell biology. Cancer Metastasis Rev 30:541-555.
82. Fleming I, Busse R. (2006). Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 47:629-633.
83. Fleming I, Michaelis UR, Bredenkotter D, et al. (2001). Endotheliumderived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88:44-51.
84. Fleming I, Rueben A, Popp R, et al. (2007a). Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 27:2612-2618.
85. Fukao M, Hattori Y, Kanno M, et al. (1997). Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium- dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Br J Pharmacol 120:439-446.
86. Funk CD. (2001). Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294:1871-1875.
87. Furchgott RF, Vanhoutte PM. (1989). Endothelium-derived relaxing and contracting factors. FASEB J 3:2007-2018.
88. Furchgott RF, Zawadzki JV. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376.
89. Gabay C, Kushner I. (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454.
90. Gao Y, Feng J, Ma K, et al. (2012). 8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in mice. PLoS One 7:e40258.
91. Gauthier KM, Edwards EM, Falck JR, et al. (2005). 14,15- Epoxyeicosatrienoic acid represents a transferable endotheliumdependent relaxing factor in bovine coronary arteries. Hypertension 45:666-671.
92. Gauthier KM, Yang W, Gross GJ, Campbell WB. (2007). Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning. J Cardiovasc Pharmacol 50:601-608.
93. Glatz JF, Storch J. (2001). Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol 12:267-274.
94. Glatz JF, van Bilsen M, Paulussen RJ, et al. (1988). Release of fatty acidbinding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 961: 148-152.
95. Grumbach IM, Chen W, Mertens SA, Harrison DG. (2005). A negative feedback mechanism involving nitric oxide and nuclear factor kappa- B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 39:595-603.
96. Guengerich FP. (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
97. Hansen TW, Mathiesen SB, Walaas SI. (1996). Bilirubin has widespread inhibitory effects on protein phosphorylation. Pediatr Res 39: 1072-1077.
98. Harder DR, Campbell WB, Roman RJ. (1995). Role of cytochrome P- 450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 32:79-92.
99. Harris RC, Homma T, Jacobson HR, Capdevila J. (1990). Epoxyeicosatrienoic acids activate Na+/H+ exchange and are mitogenic in cultured rat glomerular mesangial cells. J Cell Physiol 144: 429-437.
100. Harrison DG, Venema RC, Arnal JF, et al. (1995). The endothelial cell nitric oxide synthase: Is it really constitutively expressed? Agents Actions Suppl 45:107-117.
101. Henrichot E, Juge-Aubry CE, Pernin A, et al. (2005). Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 12: 2594-2599.
102. Hercule HC, Schunck WH, Gross V, et al. (2009). Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 29:54-60.
103. Homma T, Zhang JY, Shimizu T, et al. (1993). Cyclooxygenase-derived metabolites of 8,9-epoxyeicosatrienoic acid are potent mitogens for cultured rat glomerular mesangial cells. Biochem Biophys Res Commun 191:282-288.
104. Hopkins PN, Wu LL, Hunt SC, et al. (1996). Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16:250-255.
105. Huang A, Sun D, Jacobson A, et al. (2005). Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res 96:376-383.
106. Imig JD. (2000). Epoxygenase metabolites. Epithelial and vascular actions. Mol Biotechnol 16:233-251.
107. Imig JD. (2012). Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92:101-130.
108. Imig JD, Hammock BD. (2009). Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805.
109. Imig JD, Navar LG, Roman RJ, et al. (1996). Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370.
110. Imig JD, Simpkins AN, Renic M, Harder DR. (2011). Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev Mol Med 13:e7.
111. Inceoglu B, Schmelzer KR, Morisseau C, et al. (2007). Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82:42-49.
112. Jenkins CM, Cedars A, Gross RW. (2009). Eicosanoid signalling pathways in the heart. Cardiovasc Res 82:240-249.
113. Jiang H, Anderson GD, McGiff JC. (2010). Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP). Pharmacol Rep 62:468-474.
114. Jiang H, McGiff JC, Quilley J, et al. (2004). Identification of 5,6-transepoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem 279:36412-38418.
115. Jiang H, Quilley J, Reddy LM, et al. (2005). Red blood cells: Reservoirs of cis- and trans-epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 75:65-78.
116. Jiang JG, Chen RJ, Xiao B, et al. (2007b). Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 82: 162-174.
117. Jiang H, Zhu AG, Mamczur M, et al. (2007a). Stimulation of rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 151:1033-1040.
118. Jiang H, Zhu AG, Mamczur M, et al. (2008). Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells. J Pharmacol Exp Ther 326:330-337.
119. Karara A, Dishman E, Falck JR, Capdevila JH. (1991). Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266:7561-7569.
120. Kaspera R, Totah RA. (2009). Epoxyeicosatrienoic acids: Formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol 5:757-771.
121. Ke S, Rabson AB, Germino JF, et al. (2001). Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276:39638-39644.
122. Kim MS, Shigenaga J, Moser A, et al. (2003). Repression of farnesoid X receptor during the acute phase response. J Biol Chem 278: 8988-8995.
123. Kim DH, Vanella L, Inoue K, et al. (2010). Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARg. Stem Cells Dev 19:1863-1873.
124. Klinger MH. (1997). Platelets and inflammation. Anat Embryol (Berl) 196:1-11.
125. Kotlikoff MI. (2005). EDHF redux: EETs, TRPV4, and Ca2+ sparks. Circ Res 97:1209-1210.
126. Kozak W, Aronoff DM, Boutaud O, Kozak A. (2003). 11,12- Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide. Exp Biol Med (Maywood) 228:786-794.
127. Kozak W, Fraifeld V. (2004). Non-prostaglandin eicosanoids in fever and anapyrexia. Front Biosci 9:3339-3355.
128. Krotz F, Hellwig N, Burkle MA, et al. (2010). A sulfaphenazolesensitive EDHF opposes platelet-endothelium interactions in vitro and in the hamster microcirculation in vivo. Cardiovasc Res 85: 542-550.
129. Krotz F, Riexinger T, Buerkle MA, et al. (2004). Membrane- potentialdependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24: 595-600.
130. Kuehl Jr. FA, Egan RW. (1980). Prostaglandins, arachidonic acid, and inflammation. Science 210:978-984.
131. Kushida T, Li Volti G, Quan S, et al. (2002). Role of human heme oxygenase-1 in attenuating TNF-alpha-mediated inflammation injury in endothelial cells. J Cell Biochem 87:377-385.
132. Larsen BT, Miura H, Hatoum OA, et al. (2006). Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol 290:H491-H499.
133. Larsen BT, Zhang DX, Gutterman DD. (2007). Epoxyeicosatrienoic acids, TRP channels, and intracellular Ca2+ in the vasculature: An endothelium-derived endothelium-hyperpolarizing factor? Arterioscler Thromb Vasc Biol 27:2496-2498.
134. Lee CR, Imig JD, Edin ML, et al. (2010). Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 24: 3770-3781.
135. Lee CM, Kim BY, Li L, Morgan ET. (2008). Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem 283:889-898.
136. Lee HC, Lu T, Weintraub NL, et al. (1999). Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 519:153-168.
137. Lerman A, Zeiher AM. (2005). Endothelial function: Cardiac events. Circulation 111:363-368.
138. Levy AP, Levy NS, Wegner S, Goldberg MA. (1995). Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270:13333-13340.
139. Li PL, Campbell WB. (1997). Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
140. Li C, Hossieny P, Wu BJ, et al. (2007). Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal 9:2227-2239.
141. Li H, Forstermann U. (2000). Nitric oxide in the pathogenesis of vascular disease. J Pathol 190:244-254.
142. Li PL, Zhang DX, Ge ZD, Campbell WB. (2002). Role of ADP-ribose in 11,12-EET-induced activation of K(Ca) channels in coronary arterial smooth muscle cells. Am J Physiol Heart Circ Physiol 282: H1229-H1236.
143. Libby P. (2002). Inflammation in atherosclerosis. Nature 420:868-874.
144. Liu JY, Yang J, Inceoglu B, et al. (2010). Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79:880-887.
145. Liu Y, Zhang Y, Schmelzer K, et al. (2005). The antiinflammatory effect of laminar flow: The role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102: 16747-16752.
146. Loot AE, Popp R, Fisslthaler B, et al. (2008). Role of cytochrome P450- dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 80:445-452.
147. Loscalzo J, Welch G. (1995). Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87-104.
148. Lu T, Hong MP, Lee HC. (2005). Molecular determinants of cardiac K(ATP) channel activation by epoxyeicosatrienoic acids. J Biol Chem 280:19097-19104.
149. Lu T, Hoshi T, Weintraub NL, et al. (2001). Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol 537:811-827.
150. Lu T, Ye D, Wang X, et al. (2006). Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol 575:627-644.
151. Maines MD. (2005). The heme oxygenase system: Update 2005. Antioxid Redox Signal 7:1761-1766.
152. Matavelli LC, Huang J, Siragy HM. (2011). Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 57:308-313.
153. May MJ, Ghosh S. (1998). Signal transduction through NF-kappa B. Immunol Today 19:80-88.
154. Mazurek T, Zhang L, Zalewski A, et al. (2003). Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 108: 2460-2466.
155. McCoubrey Jr. WK, Huang TJ, Maines MD. (1997). Isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 247:725-732.
156. McGregor L, Martin J, McGregor JL. (2006). Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front Biosci 11:830-837.
157. McKay LI, Cidlowski JA. (1999). Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20:435-459.
158. Medhora M, Daniels J, Mundey K, et al. (2003). Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284:H215-H224.
159. Michaelis UR, Falck JR, Schmidt R, et al. (2005a). Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol 25:321-326.
160. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, et al. (2005b). Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 118:5489-5498.
161. Michaelis UR, Fisslthaler B, Medhora M, et al. (2003). Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J 17:770-772.
162. Michaelis UR, Fleming I. (2006). From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 111:584-595.
163. Michaelis UR, Xia N, Barbosa-Sicard E, et al. (2008). Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci 49:1242-1247.
164. Miura H, Wachtel RE, Liu Y, et al. (2001). Flow-induced dilation of human coronary arterioles: Important role of Ca(2+)-activated K(+) channels. Circulation 103:1992-1998.
165. Mohan S, Hamuro M, Sorescu GP, et al. (2003). IkappaBalphadependent regulation of low-shear flow-induced NF-kappa B activity: Role of nitric oxide. Am J Physiol Cell Physiol 284:C1039-C1047.
166. Morgan ET. (2001). Regulation of cytochrome p450 by inflammatory mediators: Why and how? Drug Metab Dispos 29:207-212.
167. Morgan ET. (2009). Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434-438.
168. Morisseau C, Hammock BD. (2005). Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45:311-333.
169. Morita T. (2005). Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 25:1786-1795.
170. Moshal KS, Zeldin DC, Sithu SD, et al. (2008). Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol 215: 771-781.
171. Ndisang JF. (2010). Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm 2010: 359732.
172. Newman JW, Morisseau C, Hammock BD. (2005). Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 44: 1-51.
173. Ng VY, Huang Y, Reddy LM, et al. (2007). Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35:1126-1134.
174. Nishimura M, Yaguti H, Yoshitsugu H, et al. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375.
175. Nithipatikom K, Gross GJ. (2010). Review article: Epoxyeicosatrienoic acids: Novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 15:112-119.
176. Nithipatikom K, Moore JM, Isbell MA, et al. (2006). Epoxyeicosatrienoic acids in cardioprotection: Ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol 291:H537-H542.
177. Node K, Huo Y, Ruan X, et al. (1999). Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
178. Node K, Ruan XL, Dai J, et al. (2001). Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276:15983-15989.
179. Norwood S, Liao J, Hammock BD, Yang GY. (2010). Epoxyeicosatrienoic acids and soluble epoxide hydrolase: Potential therapeutic targets for inflammation and its induced carcinogenesis. Am J Transl Res 2:447-457.
180. O'Donoghue M, de Lemos JA, Morrow DA, et al. (2006). Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 114:550-557.
181. Ohashi Y, Kawashima S, Hirata K, et al. (1998). Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 102: 2061-2071.
182. Oliw EH. (1994). Oxygenation of polysaturated fatty acids by cytochrome P450 monoxygenases. Prog Lipid Res 33:329-354.
183. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. (1998). Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83:932-939.
184. Otterbein LE, Soares MP, Yamashita K, Bach FH. (2003). Heme oxygenase-1: Unleashing the protective properties of heme. Trends Immunol 24:449-455.
185. Pasceri V, Wu HD, Willerson JT, Yeh ET. (2000). Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-gamma activators. Circulation 101:235-238.
186. Peng HB, Libby P, Liao JK. (1995). Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 270:14214-14219.
187. Petersson J, Zygmunt PM, Jonsson P, Hogestatt ED. (1998). Characterization of endothelium-dependent relaxation in guinea pig basilar artery - effect of hypoxia and role of cytochrome P450 monooxygenase. J Vasc Res 35:285-294.
188. Pfister SL, Gauthier KM, Campbell WB. (2010). Vascular pharmacology of epoxyeicosatrienoic acids. Adv Pharmacol 60:27-59.
189. Pober JS, Sessa WC. (2007). Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7:803-815.
190. Popp R, Fleming I, Busse R. (1998). Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor: A modulator of arterial compliance. Circ Res 82:696-703.
191. Potente M, Fisslthaler B, Busse R, Fleming I. (2003). 11,12- Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem 278:29619-29625.
192. Potente M, Michaelis UR, Fisslthaler B, et al. (2002). Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277:15671-15676.
193. Prasad S, Ravindran J, Aggarwal BB. (2010). NF-kappaB and cancer: How intimate is this relationship. Mol Cell Biochem 336:25-37.
194. Radomski MW, Moncada S. (1993). Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 70:36-41.
195. Renton KW. (2004). Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5: 235-243.
196. Revermann M. (2010). Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man. Curr Opin Pharmacol 10:173-178.
197. Ricciotti E, FitzGerald GA. (2011). Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986-1000.
198. Ridker PM, Silvertown JD. (2008). Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 79:1544-1551.
199. Roederer MW. (2009). Cytochrome P450 enzymes and genotype-guided drug therapy. Curr Opin Mol Ther 11:632-640.
200. Rompe F, Artuc M, Hallberg A, et al. (2010). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924-931.
201. Rosolowsky M, Campbell WB. (1993). Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 264:H327-H335.
202. Rosolowsky M, Falck JR, Willerson JT, Campbell WB. (1990). Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res 66: 608-621.
203. Rublevskaya I, Maines MD. (1994). Interaction of Fe-protoporphyrin IX and heme analogues with purified recombinant heme oxygenase-2, the constitutive isozyme of the brain and testes. J Biol Chem 269: 26390-26395.
204. Ryter SW, Alam J, Choi AM. (2006). Heme oxygenase-1/carbon monoxide: From basic science to therapeutic applications. Physiol Rev 86:583-650.
205. Sacerdoti D, Bolognesi M, Di Pascoli M, et al. (2006). Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am J Physiol Heart Circ Physiol 291: H1999-H2002.
206. Sacerdoti D, Colombrita C, Di Pascoli M, et al. (2007). 11,12- Epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. Prostaglandins Other Lipid Mediat 82:155-161.
207. Savoia C, Sada L, Zezza L, et al. (2011). Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens 2011:281240.
208. Schwertner HA, Jackson WG, Tolan G. (1994). Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40:18-23.
209. Seldon MP, Silva G, Pejanovic N, et al. (2007). Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of NF-kappaB RelA phosphorylation at serine 276. J Immunol 179:7840-7851.
210. Sethi G, Sung B, Aggarwal BB. (2008). Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med (Maywood) 233:21-31.
211. Seubert JM, Sinal CJ, Graves J, et al. (2006). Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
212. Seubert J, Yang B, Bradbury JA, et al. (2004). Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44-MAPK pathway. Circ Res 95:506-514.
213. Shen HC, Ding FX, Wang S, et al. (2009). Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem 52:5009-5012.
214. Simpkins AN, Rudic RD, Schreihofer DA, et al. (2009). Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174:2086-2095.
215. Snyder GD, Krishna UM, Falck JR, Spector AA. (2002). Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am J Physiol Heart Circ Physiol 283: H1936-H1942.
216. Soares MP, Seldon MP, Gregoire IP, et al. (2004). Heme oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol 172:3553-3563.
217. Spearman ME, Prough RA, Estabrook RW, et al. (1985). Novel glutathione conjugates formed from epoxyeicosatrienoic acids (EETs). Arch Biochem Biophys 242:225-230.
218. Spector AA. (2009). Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50:S52-S56.
219. Spector AA, Fang X, Snyder GD, Weintraub NL. (2004). Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog Lipid Res 43:55-90.
220. Spector AA, Norris AW. (2007). Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292: C996-C1012.
221. Spiecker M, Peng HB, Liao JK. (1997). Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem 272:30969-30974.
222. Stenvinkel P. (2001). Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transplant 16:1968-1971.
223. Stocker R. (2004). Antioxidant activities of bile pigments. Antioxid Redox Signal 6:841-849.
224. Sudhahar V, Shaw S, Imig JD. (2010). Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem 17:1181-1190.
225. Sun J, Sui X, Bradbury JA, et al. (2002). Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90:1020-1027.
226. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD. (2004). Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32:359-363.
227. Thanassoulis G, Massaro JM, Corsini E, et al. (2012). Periaortic adipose tissue and aortic dimensions in the Framingham Heart Study. J Am Heart Assoc 1:e000885.
228. Theken KN, Deng Y, Kannon MA, et al. (2011). Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos 39:22-29.
229. Traub O, Berk BC. (1998). Laminar shear stress: Mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 18:677-685.
230. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. (2010). Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 11:700-714.
231. Vanella L, Kim DH, Sodhi K, et al. (2011). Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes. Prostaglandins Other Lipid Mediat 96:54-62.
232. Veerkamp JH, Zimmerman AW. (2001). Fatty acid-binding proteins of nervous tissue. J Mol Neurosci 16:133-142 (discussion 151-157).
233. Viswanathan K, Kilcullen N, Morrell C, et al. (2010). Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 55:2590-2598.
234. Vriens J, Owsianik G, Fisslthaler B, et al. (2005). Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97:908-915.
235. Wadgaonkar R, Pierce JW, Somnay K, et al. (2004). Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. Am J Respir Cell Mol Biol 31:423-431.
236. Wagener FA, da Silva JL, Farley T, et al. (1999). Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. J Pharmacol Exp Ther 291: 416-423.
237. Wagener FA, Volk HD, Willis D, et al. (2003). Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 55: 551-571.
238. Wang D, Dubois RN. (2012). Epoxyeicosatrienoic acids: A doubleedged sword in cardiovascular diseases and cancer. J Clin Invest 122: 19-22.
239. Wang H, Lin L, Jiang J, et al. (2003). Up-regulation of endothelial nitricoxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 307:753-764.
240. Wang N, Verna L, Chen NG, et al. (2002). Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses proinflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem 277:34176-34181.
241. Wang HX, Zhang DM, Zeng XJ, et al. (2012). Upregulation of cytochrome P450 2J3/11,12-epoxyeicosatrienoic acid inhibits apoptosis in neonatal rat cardiomyocytes by a caspase-dependent pathway. Cytokine 60:360-368.
242. Watanabe H, Vriens J, Prenen J, et al. (2003). Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424:434-438.
243. Webler AC, Michaelis UR, Popp R, et al. (2008a). Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol 295:C1292-C1301.
244. Webler AC, Popp R, Korff T, et al. (2008b). Cytochrome P450 2C9- induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol 28:1123-1129.
245. Weintraub NL, Fang X, Kaduce TL, et al. (1997). Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81:258-267.
246. Weintraub NL, Fang X, Kaduce TL, et al. (1999). Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids. Am J Physiol 277:H2098-H2108.
247. Weston AH, Feletou M, Vanhoutte PM, et al. (2005). Bradykinininduced, endothelium-dependent responses in porcine coronary arteries: Involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol 145:775-784.
248. Widstrom RL, Norris AW, Spector AA. (2001). Binding of cytochrome P450 monooxygenase and lipoxygenase pathway products by heart fatty acid-binding protein. Biochemistry 40:1070-1076.
249. Widstrom RL, Norris AW, Van Der Veer J, Spector AA. (2003). Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry 42: 11762-11767.
250. Willis D, Moore AR, Frederick R, Willoughby DA. (1996). Heme oxygenase: A novel target for the modulation of the inflammatory response. Nat Med 2:87-90.
251. Wong PY, Lai PS, Falck Jr. (2000). Mechanism and signal transduction of 14(R), 15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in guinea pig monocytes. Prostaglandins Other Lipid Mediat 62: 321-333.
252. Wong PY, Lai PS, Shen SY, et al. (1997). Post-receptor signal transduction and regulation of 14(R),15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells. J Lipid Mediat Cell Signal 16: 155-169.
253. Wong PY, Lin KT, Yan YT, et al. (1993). 14(R),15(S)-epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in guinea pig mononuclear cell membranes. J Lipid Mediat 6:199-208.
254. Wu BJ, Chen K, Barter PJ, Rye KA. (2012). Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 125: 150-158.
255. Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468.
256. Xiao YF, Huang L, Morgan JP. (1998). Cytochrome P450: A novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 508:777-792.
257. Xiao YF, Ke Q, Seubert JM, et al. (2004). Enhancement of cardiac Ltype Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol 66:1607-1616.
258. Xu X, Zhang XA, Wang DW. (2011). The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 63:597-609.
259. Yamamoto T, Yamamoto A, Watanabe M, et al. (2009). Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues. Biotechnol Lett 31:1695-1701.
260. Yan G, Chen S, You B, Sun J. (2008). Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res 78: 308-314.
261. Yang S, Lin L, Chen JX, et al. (2007). Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 293:H142-H151.
262. Yang W, Tuniki VR, Anjaiah S, et al. (2008). Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324:1019-1027.
263. Yao X, Garland CJ. (2005). Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res 97: 853-863.
264. Ye D, Zhou W, Lee HC. (2005). Activation of rat mesenteric arterial KATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 288:H358-H364.
265. Ye D, Zhou W, Lu T, et al. (2006). Mechanism of rat mesenteric arterial KATP channel activation by 14,15-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 290:H1326-H1336.
266. Ying L, Hofseth LJ. (2007). An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 67: 1407-1410.
267. Yu S, Reddy JK. (2007). Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 1771: 936-951.
268. Zeldin DC. (2001). Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276:36059-36062.
269. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. (1995). Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 322:76-86.
270. Zeldin DC, Foley J, Ma J, et al. (1996a). CYP2J subfamily P450s in the lung: Expression, localization, and potential functional significance. Mol Pharmacol 50:1111-1117.
271. Zeldin DC, Kobayashi J, Falck JR, et al. (1993). Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402-6407.
272. Zeldin DC, Moomaw CR, Jesse N, et al. (1996b). Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330: 87-96.
273. Zhang B, Cao H, Rao GN. (2006). Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 281:905-914.
274. Zhang JY, Prakash C, Yamashita K, Blair IA. (1992). Regiospecific and enantioselective metabolism of 8,9-epoxyeicosatrienoic acid by cyclooxygenase. Biochem Biophys Res Commun 183:138-143.
275. Zhang W, Otsuka T, Sugo N, et al. (2008). Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39:2073-2078.
276. Zhao G, Wang J, Xu X, et al. (2012). Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-a-induced injury. J Lipid Res 53:456-466.
277. Zhu Y, Schieber EB, McGiff JC, Balazy M. (1995). Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25:854-859.
278. Zordoky BN, El-Kadi AO. (2010). Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther 125:446-463.
279. Zou AP, Fleming JT, Falck JR, et al. (1996). Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. Am J Physiol 270:F822-F832.
280. Zygmunt PM, Edwards G, Weston AH, et al. (1996). Effects of cytochrome P450 inhibitors on EDHF-mediated relaxation in the rat hepatic artery. Br J Pharmacol 118:1147-1152.